In this retrospective analysis of prospectively collected data, patients between the ages of 18 and 100 years who were treated for breast cancer at the Department of Gynecology and the Department of Internal Medicine I (Oncology) of the Medical University of Vienna between January 1980 and May 2019 were included.
Liver function protein levels measured 6 months prior to the diagnosis of BCLM, at the time of diagnosis, and 12 months after diagnosis were acquired. These included AST, ALT, GGT, LDH, AP, albumin, and bilirubin. Moreover, data on tumors including molecular subtype (luminal A, luminal B, HER2-positive, or triple negative), tumor type (invasive ductal carcinoma or invasive lobular carcinoma), and grading (I–III); age (years); body mass index (BMI in kg/m2); history of smoking (yes/no); history of alcohol consumption (yes/no); and whether any prescribed medications were potentially toxic to the liver (yes/no) were collected. Normal ranges of values were defined as our institution’s local standard (Table 1 ). The study was approved by a local ethics committee (number EK 1488/2019).
Liver function protein levels measured 6 months prior to the diagnosis of BCLM, at the time of diagnosis, and 12 months after diagnosis were acquired. These included AST, ALT, GGT, LDH, AP, albumin, and bilirubin. Moreover, data on tumors including molecular subtype (luminal A, luminal B, HER2-positive, or triple negative), tumor type (invasive ductal carcinoma or invasive lobular carcinoma), and grading (I–III); age (years); body mass index (BMI in kg/m2); history of smoking (yes/no); history of alcohol consumption (yes/no); and whether any prescribed medications were potentially toxic to the liver (yes/no) were collected. Normal ranges of values were defined as our institution’s local standard (
Free full text: Click here
